Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
Fiscal first quarter ended December 31, 2020; comparisons are with the three months ended December 31, 2019 unless noted. Enanta is a biotechnology company whose revenue is primarily royalties from AbbVie’s hepatitis C (HCV) regimen MAVYRET/MAVIRET. Royalty income supports wholly owned drug-development programs in RSV, HBV, SARS-CoV-2, hMPV and NASH. Amounts below are in millions of dollars unless otherwise stated.
Financial performance and liquidity
| Metric | Q1 FY2021 | Q1 FY2020 |
|---|---|---|
| Royalty revenue | $31.7 | $52.6 |
| Research and development expense | $36.7 | $32.8 |
| General and administrative expense | $7.4 | $6.9 |
| Total operating expenses | $44.0 | $39.7 |
| Operating income (loss) | $(12.3) | $12.9 |
| Net income (loss) | $(8.3) | $13.4 |
| Basic and diluted EPS | $(0.41) | $0.68 basic; $0.65 diluted |
| Operating cash flow | $(14.9) | $12.4 |
Royalty revenue fell 39.6%; AbbVie reported worldwide MAVYRET/MAVIRET sales of $481 million, down from $628 million. R&D expense increased 11.9%, while total operating expenses rose 10.9%. Operating and net margins were negative in the quarter; gross margin is not applicable to the disclosed royalty-led revenue model.
At December 31, 2020, cash and cash equivalents were $55.1 million, short-term marketable securities $331.1 million, and long-term marketable securities $18.5 million, totaling $404.7 million in cash, cash equivalents and marketable securities. Current assets were $445.9 million and current liabilities $23.0 million. The company reported no conventional borrowings; obligations included operating lease liabilities of $8.7 million in total and $1.5 million of Series 1 nonconvertible preferred stock classified as a liability. Total liabilities were $29.0 million and stockholders’ equity $452.0 million.
Cash, cash equivalents and restricted cash decreased $32.0 million during the quarter. Investing activities used $17.4 million, primarily reflecting net purchases of marketable securities; financing provided $0.3 million. The filing reports no material impact from adopting the expected-credit-loss accounting standard.
Material changes versus the prior comparable period
- Royalty revenue declined $20.8 million, which management attributed primarily to fewer HCV patient starts amid the COVID-19 pandemic. AbbVie’s reported regimen sales declined about 23%.
- The company shifted from operating income to an operating loss and from net income to a net loss.
- R&D spending rose $3.9 million, mainly due to the timing and advancement of virology studies; lower liver-program clinical-trial costs partly offset the increase.
- Other income fell to $0.7 million from $2.1 million, chiefly because of lower investment income and interest rates.
- Cash used in operations increased by $27.3 million year over year, reflecting the lower earnings and working-capital movements.
Outlook, management commentary, risks and unusual items
- Management expected fiscal 2021 expenses to exceed revenue and R&D expense to increase versus fiscal 2020 as programs advance. It stated current liquidity should fund operations for the foreseeable future, while noting that this assessment is forward-looking and depends on royalties, spending and clinical progress.
- COVID-19 had reduced HCV diagnoses, treatment and royalty revenue and disrupted clinical-trial recruitment. RSV prevalence remained unusually low, affecting the RSVP study; the timing of a return to normal RSV activity was uncertain. Some trials paused recruitment in March 2020 and resumed in July 2020. Contract manufacturers were operating near normal levels at the time of the report, but future supply or trial disruption remained possible.
- Program milestones described included initiation of the Phase 2b RSVTx study in December 2020; expected initiation of the pediatric RSVPEDs study in Q1 calendar 2021; anticipated EDP-514 topline results in Q2 2021; planned EDP-721 Phase 1 initiation around mid-2021; and expected mid-2021 preliminary EDP-297 data and an interim ARGON-2 analysis. These are plans and expectations, not guarantees.
- The quarter’s $3.3 million income-tax benefit reflected the company’s ability and intent to carry back its current-year tax loss under the CARES Act. A valuation allowance remained against the majority of deferred tax assets.
- No litigation was pending, no indemnification liability was accrued, and the filing reported no material change in contractual commitments. The company disclosed no off-balance-sheet financing arrangements. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting.
- Key risks include reliance on AbbVie royalties, further HCV price or volume pressure, clinical failure or delay, COVID-19 effects, competition, dependence on third-party manufacturers and trial operators, and potential need for additional financing if royalties fall substantially.
Most important facts for investors to verify
- Whether HCV treatment volumes and AbbVie’s MAVYRET/MAVIRET sales recover, and how this translates into Enanta’s tiered royalties.
- Actual quarterly cash burn and whether the stated liquidity runway remains adequate as development spending increases.
- Enrollment, timing and results for EDP-938, EDP-514, EDP-721, EDP-305 and EDP-297, particularly given pandemic-related disruption.
- Whether planned trial milestones and expected 2021 data releases occur on schedule, and whether results support continued investment or partnering.
- Any change in the company’s reliance on AbbVie, HCV competition or pricing, clinical and manufacturing risks, tax-asset valuation, or potential financing needs.